<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152395</url>
  </required_header>
  <id_info>
    <org_study_id>Metabolic syndrome in EVAR</org_study_id>
    <nct_id>NCT04152395</nct_id>
  </id_info>
  <brief_title>Metabolic Syndrome in Patients Undergoing Endovascular Aortic Repair (EVAR)</brief_title>
  <official_title>Study of Metabolic Syndrome in Patients Undergoing Endovascular Aortic Repair (EVAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Thessaly</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Thessaly</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study aims to identify the prevalence of metabolic syndrome in patients
      undergoing EVAR and the implications of metabolic syndrome on the postoperative outcome, the
      major complications, the thromboembolic events and the perioperative mortality and morbidity
      of the patients undergoing vascular surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients scheduled for elective EVAR will be randomly divided in two groups. One group
      patients with metabolic syndrome and one without.

      Metabolic syndrome is defined by the definition of 2009 as:

      Increased waist circumflex (&gt;94 cm in men and &gt; 80 cm in women), increased triglycerides or
      in therapy, decreased HDL (&lt; 40 mg/dl in men and &lt;50mg/dl in women) or in therapy, Increased
      blood pressure (Systolic Blood Pressure&gt;130 mmHg or Diastolic Blood Pressure&gt;85 mmHg) or in
      therapy, increased fasting glucose (&gt;100mg/dl) or in therapy.

      All the patients will be monitored throughout the perioperative period, at 30 days, 6 and 12
      months, and any major or minor complication will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 11, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Patients after EVAR who died in 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>6 months</time_frame>
    <description>Patients after EVAR who died in 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 months</time_frame>
    <description>Patients after EVAR who died in 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systematic inflammatory response</measure>
    <time_frame>30 days</time_frame>
    <description>Patients after EVAR that develop Systematic inflammatory response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systematic inflammatory response</measure>
    <time_frame>6 months</time_frame>
    <description>Patients after EVAR that develop Systematic inflammatory response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systematic inflammatory response</measure>
    <time_frame>12 months</time_frame>
    <description>Patients after EVAR that develop Systematic inflammatory response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postimplantation syndrome</measure>
    <time_frame>30 days</time_frame>
    <description>Patients after EVAR that develop Postimplantation syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postimplantation syndrome</measure>
    <time_frame>6 months</time_frame>
    <description>Patients after EVAR that develop Postimplantation syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postimplantation syndrome</measure>
    <time_frame>12 months</time_frame>
    <description>Patients after EVAR that develop Postimplantation syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal insufficiency</measure>
    <time_frame>30 days</time_frame>
    <description>Patients after EVAR that develop Renal insufficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal insufficiency</measure>
    <time_frame>6 months</time_frame>
    <description>Patients after EVAR that develop Renal insufficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal insufficiency</measure>
    <time_frame>12 months</time_frame>
    <description>Patients after EVAR that develop Renal insufficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of cardiovascular events in patients after EVAR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of cardiovascular events in patients after EVAR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of cardiovascular events in patients after EVAR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic events</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of thromboembolic events in patients after EVAR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic events</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of thromboembolic events in patients after EVAR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic events</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of thromboembolic events in patients after EVAR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of surgical procedure</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of Complications of surgical procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of surgical procedure</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of Complications of surgical procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of surgical procedure</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of Complications of surgical procedure</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Postoperative delirium (POD)</measure>
    <time_frame>30 days, 6 and 12 months</time_frame>
    <description>Prevalence of POD in patients undergoing EVAR</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Endovascular Aortic Repair</condition>
  <arm_group>
    <arm_group_label>Metabolic group</arm_group_label>
    <description>Patients with metabolic syndrome undergoing EVAR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients without metabolic syndrome undergoing EVAR</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EVAR</intervention_name>
    <description>Patients undergoing EVAR</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Metabolic group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients scheduled for elective EVAR
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective EVAR

        Exclusion Criteria:

          -  Patients incapable to give informed consent

          -  Pregnancy

          -  Cancer

          -  Systematic Inflammatory disease

          -  Use of steroids

          -  Emergency surgery

          -  Prior ICU admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Elena Arnaoutoglou, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Thessaly</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haralampos Milionis, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Ioannina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Konstantina Kolonia, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Larissa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Konstantina Kolonia, MD</last_name>
    <phone>+306958261393</phone>
    <email>kon.kolonia@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Metaxia Bareka, MD, PhD</last_name>
    <phone>+306947845083</phone>
    <email>barekametaxia@hotmail.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 Oct 20;120(16):1640-5. doi: 10.1161/CIRCULATIONAHA.109.192644. Epub 2009 Oct 5.</citation>
    <PMID>19805654</PMID>
  </results_reference>
  <results_reference>
    <citation>Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet. 2005 Sep 24-30;366(9491):1059-62.</citation>
    <PMID>16182882</PMID>
  </results_reference>
  <results_reference>
    <citation>Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Fernando Costa. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol. 2005 Dec;4(4):198-203.</citation>
    <PMID>18340209</PMID>
  </results_reference>
  <results_reference>
    <citation>Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA. 2015 May 19;313(19):1973-4. doi: 10.1001/jama.2015.4260.</citation>
    <PMID>25988468</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>May 25, 2020</last_update_submitted>
  <last_update_submitted_qc>May 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Thessaly</investigator_affiliation>
    <investigator_full_name>Elena Arnaoutoglou</investigator_full_name>
    <investigator_title>Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>EVAR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

